Trending Now
NantKwest Inc. (NASDAQ:NK) And ImmunityBio Add Cohort 3 In Phase 2...
NantKwest Inc. (NASDAQ:NK) has announced the addition of a third cohort to its ongoing Phase 2 study if its novel immunotherapy for the treatment...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Halozyme ($HALO): Analyzing the Latest Wall Street Insights and Forecasts
Halozyme Therapeutics (HALO) has been attracting considerable attention from Wall Street analysts, and for good reason. As a biopharmaceutical company specializing in...
MAKE IT MODERN
LATEST REVIEWS
Corcept Therapeutics Incorporated (NASDAQ:CORT) Reports Revenue of $86.3 Million In Q3...
Corcept Therapeutics Incorporated (NASDAQ:CORT) has announced its Q3 2020 financial results in which revenue grew 6% YoY to $86.3 million.
Corcept revises its FY2020 financial...
MAKE IT MODERN
PERFORMANCE TRAINING
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Dose First Patient In Selinexor Study In combination With standard...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced that it has dosed the first patient in its Phase 1/2 clinical trial for the evaluation of oral...
Why Small-Cap Biotech Stocks are a Speculator’s Best Friend (INMD, ATRX, DVAX, SAVA, ICPT,...
Bloomberg reports this week that the VIX (the CBOE Volatility Index) is rallying with the S&P 500 in a rare way over...
Protagonist Therapeutics Inc (NASDAQ: PTGX) Receives Positive Results From the Phase II Study of...
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced that it has received positive results from its Phase II study of PN-943 in moderate or...
OneMedNet (ONMD) Reports Impressive Five-Fold Revenue Increase
OneMedNet Corporation (NASDAQ: ONMD) has reported a remarkable five-fold increase in revenue for 2023, driven by the growing demand for its regulatory-grade...
Alexion (NASDAQ:ALXN) Receives FDA Approval For ULTOMIRIS® 100 mg/mL Formulation In Treating PNH and...
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) has received approval from the US FDA for ULTOMIRIS® (ravlizumab-cwvz) 100mg/mL formulation.
ULTOMIRIS® can reduce the time spent to receive treatment...
MAKE IT MODERN
